Is mavacamten currently approved for sale in China?

Mavacamten is a new type of myocardial contraction inhibitor, mainly used to treat hypertrophic obstructive cardiomyopathy (HCM). By selectively regulating cardiac myosin activity, it reduces excessive cardiac contraction and improves cardiac diastolic function, thereby alleviating patients' reduced exercise tolerance and heart failure symptoms. According to the latest information, Mavakatai Capsules have been officially approved for sale in China and have been included in my country’s medical insurance system. Patients can purchase them through regular hospital pharmacies or medical insurance channels.

In the domestic market, the price of Mavakatai capsules is relatively high. The price of the European version of the original drug is about RMB between 20,000 and 50,000 yuan. The price of the American version of the original drug is even higher, about RMB 60,000. Since the drug is a high-value innovative drug, patients can obtain partial reductions through medical insurance reimbursement. The specific reimbursement policy and ratio need to be checked according to the latest information provided by local hospitals or pharmacies. For HCM patients who require long-term medication, medical insurance coverage can undoubtedly reduce the financial burden.

In overseas markets, generic drugs of Mavakatai Capsules have also been launched, such as the Laos Lucius version of the generic drug, the specifications are basically the same as the original drug, but the price is significantly lower than the original drug, currently about more than 1,000 yuan. This provides an affordable alternative for patients who cannot afford the high-priced original drugs. At the same time, the ingredients and efficacy of generic drugs are basically the same as the original drugs and can meet the needs of clinical use.

Clinically, Mavaceta is suitable for adult patients with symptoms of hypertrophic obstructive cardiomyopathy who need to improve exercise tolerance. During use, patients need to regularly monitor left ventricular outflow tract pressure difference, cardiac function indicators and drug blood concentration under the guidance of a cardiologist to ensure efficacy and safety. For patients with limited budget, they can choose domestic original drugs reimbursed by medical insurance or lower-priced overseas generic versions based on doctor's advice to achieve a balance between economy and efficacy.

Reference link:https://www.drugs.com